Protagonist Therapeutics, Inc.
PTGX
$96.75
$4.394.75%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -133.71% | -18.46% | -13.57% | -105.62% | 381.70% |
| Total Depreciation and Amortization | -261.75% | -27.82% | -2.24% | -1.46% | -35.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 72.76% | 21.11% | 23.56% | 48.87% | 20.56% |
| Change in Net Operating Assets | 98.41% | 1,168.18% | -101.33% | 151.24% | -918.96% |
| Cash from Operations | -26.72% | 93.05% | -110.71% | 557.05% | -272.04% |
| Capital Expenditure | 53.55% | 88.65% | -2,803.57% | -125.21% | -1,531.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 681.81% | 71.88% | 163.14% | -1,586.73% | 86.27% |
| Cash from Investing | 659.48% | 71.94% | 162.20% | -1,654.97% | 85.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -29.62% | -53.04% | 13.72% | 52.87% | 664.90% |
| Repurchase of Common Stock | -- | -- | -- | 20.17% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -29.62% | -53.04% | 13.72% | 58.95% | 664.90% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 143.33% | 75.58% | -84.18% | 399.48% | 22.67% |